00:36 , May 7, 2016 |  BC Extra  |  Company News

Newco Vitaeris licenses Alder's clazakizumab

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) granted newco Vitaeris Inc. (Vancouver, B.C.) exclusive, worldwide rights to anti-IL-6 mAb clazakizumab (formerly ALD518 ). Alder helped co-found Vitaeris to house clazakizumab, which the newco intends to develop for chronic...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Aurinia Pharmaceuticals management update

Aurinia Pharmaceuticals Inc. (TSX-V:AUP), Victoria, B.C.   Business: Autoimmune, Transplant, Diagnostic   Hired: Richard Glickman as executive chairman and acting CEO, co-founder and formerly chairman and CEO of Aspreva Pharmaceuticals Corp. , which Galenica Ltd....
08:00 , Dec 17, 2012 |  BioCentury  |  Finance

Maple leaf windfall

The $510.3 million Gilead Sciences Inc. will pay to take out YM BioSciences Inc. puts the deal in the top five transactions involving a Canadian biopharma company in the past five years. Gilead (NASDAQ:GILD) will...
07:00 , May 14, 2012 |  BioCentury  |  Strategy

Teva: No more silos

Teva Pharmaceutical Industries Ltd. 's new CSO and president of global R&D, Michael Hayden, plans to break down the silos housing generics and branded R&D with the aim of improving both businesses while better serving...
01:24 , May 9, 2012 |  BC Extra  |  Company News

Teva names Hayden CSO

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) hired Michael Hayden as CSO and president of global R&D. Hayden is currently a professor of medical genetics at the University of British Columbia and is Canada Research Chair in...
07:00 , Jul 12, 2010 |  BioCentury  |  Strategy

Biogen Idec's Agenda

Of all the first generation big cap biotechs, Biogen Idec Inc. has always been known as the stodgy one. Ironically, it has taken the intervention of activist investors - generally thought of as green eyeshade...
07:00 , Apr 13, 2009 |  BC Week In Review  |  Company News

Protox management update

Protox Therapeutics Inc. (TSX:PRX), Vancouver, B.C.   Business: Cancer   Hired: John Parkinson as CFO, formerly VP of finance at Aspreva Pharmaceuticals Corp. (now part of Galenica Ltd. ); he replaces VP of Finance and...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

BaroFold management update

BaroFold Inc. , Boulder, Colo.   Business: Proteomics, Autoimmune, Inflammation   Hired: J. William Freytag as president and CEO, formerly chairman and CEO of Aspreva Pharmaceuticals Corp. (now part of Galenica Ltd. )  ...
02:37 , Jan 29, 2009 |  BC Extra  |  Company News

BaroFold names Freytag CEO

Proteomics, autoimmune and inflammation company BaroFold (Boulder, Colo.) hired J. William Freytag as president and CEO. Previously, he was chairman and CEO of Aspreva , now part of Galenica (SWX:GALN)....
07:00 , Aug 18, 2008 |  BioCentury  |  Finance

Ebb & Flow

Investors reached new heights of optimism after a special committee of three independent Genentech board members rejected Roche ’s offer to buy the 44.1% of the biotech it doesn’t own for $89 a share, or...